Study of 124I-NM404 in Advanced Solid Malignancies

Stopped early

Conditions studied: Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer

In brief

The purpose of this study is to assess the use of investigational compound 124I-NM404 for accurate detection and characterization of a wide variety of solid primary and metastatic malignancies anywhere in the body.

Key facts

Study ID

NCT01662284

Run by

University of Wisconsin, Madison

People needed

12

Starts

2012-07-01

Expected to finish

2016-05-01

Last updated by the study team

2019-11-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of advanced solid malignancy.
• Allowed tumor types: triple negative breast, prostate, colorectal, gastric, ovarian, pancreatic, esophageal, soft tissue sarcoma, and head \& neck cancer
• Disease must be at least 1cm in diameter
• Brain metastasis must be stable for at least one month.
• ECOG performance status 0-2
• Anticipated survival less than 5 years, as per the treating physician

You may not qualify if…

• Skin lesions only
• Chemotherapy or radiotherapy within 1 week
• Residual toxicities of grade 2 or greater from prior therapy
• Adequate organ function as per specified laboratory parameter
• Platelet count > or = to 75,000/uL

Where it is running

• University of Wisconsin Carbone Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.